Evidence map›Paper›PMID 23665909›Full record

ArticleEnvironmental health perspectives2013

N-6-adenine-specific DNA methyltransferase 1 (N6AMT1) polymorphisms and arsenic methylation in Andean women.

Florencia Harari, Karin Engström, Gabriela Concha, Graciela Colque, Marie Vahter, Karin Broberg

Open access · diamondAbstract read
In one paragraph

Article in Environmental health perspectives, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. CytosolicProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Serum Folate and Vitamin BDiabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  4. Epigenomic reprogramming in iAs-mediated carcinogenesis.Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Association ofFrontiers in pharmacology · 2018
    Article
  11. In vivo and in vitro methods for evaluating soil arsenic bioavailability: relevant to human health risk assessment.Journal of toxicology and environmental health. Part B, Critical reviews · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Linkage Analysis of Urine Arsenic Species Patterns in the Strong Heart Family Study.Toxicological sciences : an official journal of the Society of Toxicology · 2015
    Article
  17. Interactive Effects of N6AMT1 and As3MT in Arsenic Biomethylation.Toxicological sciences : an official journal of the Society of Toxicology · 2015
    Article
  18. Emerging approaches in predictive toxicology.Environmental and molecular mutagenesis · 2014
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Florencia HarariInstitute of Environmental Medicine, Unit of Metals and Health, Karolinska Institutet, Stockholm, Sweden.
Karin Engström
Gabriela Concha
Graciela Colque
Marie Vahter
Karin Broberg
Karolinska Institutet · SELund University · SENational Food Administration · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn humans, inorganic arsenic is metabolized to methylated metabolites mainly by arsenic (+3 oxidation state) methyltransferase (AS3MT). AS3MT polymorphisms are associated with arsenic metabolism efficiency. Recently, a putative N-6-adenine-specific DNA methyltransferase 1 (N6AMT1) was found to methylate arsenic in vitro.

objectiveWe evaluated the role of N6AMT1 polymorphisms in arsenic methylation efficiency in humans.

methodsWe assessed arsenic methylation efficiency in 188 women exposed to arsenic via drinking water (~ 200 µg/L) in the Argentinean Andes by measuring the relative concentrations of arsenic metabolites in urine [inorganic arsenic, methylarsonic acid (MMA), and dimethylarsinic acid] by high-performance liquid chromatography coupled with hydride generation and inductively coupled plasma mass spectrometry. We performed genotyping for N6AMT1 and AS3MT polymorphisms by Taqman assays, and gene expression (in blood; n = 63) with Illumina HumanHT-12 v4.0.

resultsFive N6AMT1 single nucleotide polymorphisms (SNPs; rs1997605, rs2205449, rs2705671, rs16983411, and rs1048546) and two N6AMT1 haplotypes were significantly associated with the percentage of MMA (%MMA) in urine, even after adjusting for AS3MT haplotype. %MMA increased monotonically according to the number of alleles for each SNP (e.g., for rs1048546, mean %MMA was 7.5% for GG, 8.8% for GT, and 9.7% for TT carriers). Three SNPs were in linkage disequilibrium (R2 > 0.8). Estimated associations for joint effects of N6AMT1 (haplotype 1) and AS3MT (haplotype 2) were generally consistent with expectations for additive effects of each haplotype on %MMA. Carriers of N6AMT1 genotypes associated with lower %MMA showed the lowest N6AMT1 expression, but associations were monotonic according to copy number for only one genotype and one haplotype.

conclusionsN6AMT1 polymorphisms were associated with arsenic methylation in Andean women, independent of AS3MT. N6AMT1 polymorphisms may be susceptibility markers for arsenic-related toxic effects.

Indexed as

Polymorphism, GeneticAdultArgentinaArsenicArsenicalsCacodylic AcidChromatography, High Pressure LiquidFemaleHaplotypesHumansMass SpectrometryMethylationMethyltransferasesMiddle AgedPolymorphism, Single NucleotideReal-Time Polymerase Chain ReactionArsenicArsenicalsAS3MT protein, humanCacodylic AcidMethyltransferasesmonomethylarsonic acidSite-Specific DNA-Methyltransferase (Adenine-Specific)

Identifiers

PMID23665909
PMCPMC3702000
OpenAlexW2089747160

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.